Avineuro Pharmaceuticals, Inc.
A Global Neuroscience Research And Development Company Developing novel small molecules to treat unmet medical needs in the neurological and psychiatric fields.

San Diego, CA – June 22nd, 2009 – Avineuro Pharmaceuticals, Inc. announced today an initiation of a two-armed, double-blinded, placebo- and a reference drug- controlled Phase II clinical studies of AVN-397, a potent small molecule for treatment of anxiety and Alzheimer’s disease. Avineuro Pharmaceuticals, Inc. will present at ICAD 2009 in Vienna, Austria in July.

Yan Lavrovsky, CEO
Avineuro Pharmaceuticals, Inc.
6605 Nancy Ridge Drive, Suite 126
San Diego, CA 92121
Tel 858-436-1537 / 858-436-1540
Fax 858-228-9798
Email: YLavrovsky@avineuro.com